Likun Chen

2.8k total citations · 1 hit paper
86 papers, 1.5k citations indexed

About

Likun Chen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Likun Chen has authored 86 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 48 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Likun Chen's work include Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (32 papers) and Brain Metastases and Treatment (11 papers). Likun Chen is often cited by papers focused on Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (32 papers) and Brain Metastases and Treatment (11 papers). Likun Chen collaborates with scholars based in China, United States and Hong Kong. Likun Chen's co-authors include Xue Hou, Hongyun Zhao, Yan Huang, Yuanyuan Zhao, Li Zhang, Yuxiang Ma, Yunpeng Yang, Ningning Zhou, Wenfeng Fang and Liwu Fu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Likun Chen

79 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

2018 326 citations Wenfeng Fang, Yunpeng Yang et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Likun Chen

Since Specialization

Citations

This map shows the geographic impact of Likun Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Likun Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Likun Chen more than expected).

Fields of papers citing papers by Likun Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Likun Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Likun Chen. The network helps show where Likun Chen may publish in the future.

Co-authorship network of co-authors of Likun Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Likun Chen. A scholar is included among the top collaborators of Likun Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Likun Chen. Likun Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases 2025 ·npj Precision Oncology ·Jing Chen, (unknown), Meichen Li, Hui Yu, (unknown), (unknown), Xue Hou, Likun Chen	0
2	Prognostic Nutritional Index Predicts Efficacy and Immune-Related Adverse Events of First-Line Chemoimmunotherapy in Patients with Extensive-Stage Small-Cell Lung Cancer 2024 ·Journal of Inflammation Research ·(unknown), Jing Chen, (unknown), Meichen Li, Muyan Cai, Likun Chen	2
3	Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study 2023 ·Cancer Medicine ·Likun Chen, (unknown), Timuçin Çil, (unknown), İrfan Çiçin, Yihong Shen, Zhihua Liu, Özgür Özyılkan, (unknown), Jun Chen, (unknown), Zhendong Chen, Helong Zhang, (unknown), Qingfeng Dong, (unknown), Jin‐Chen Yu, Li Zhang	3
4	N6 -Methyladenosine Promotes Translation of VEGFA to Accelerate Angiogenesis in Lung Cancer 2023 ·Cancer Research ·(unknown), Jiawang Zhou, Jiexin Li, Zhaotong Wang, Zhuojia Chen, (unknown), Lichen Ge, Guoyou Xie, (unknown), (unknown), Hongbing Huang, Likun Chen, Hongsheng Wang	42
5	Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced Non-Squamous Non-Small-Cell lung cancer 2023 ·International Immunopharmacology ·Hui Yu, Jingyu Chen, Yixin Zhou, Sheng Jin, Xuanye Zhang, Lina He, Likun Chen, Qian Chu, Zhang Li, (unknown)	7
6	Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study 2023 ·Journal of Thoracic Oncology ·Xue Hou, Chengzhi Zhou, Guowu Wu, Lin Wen, Zhanhong Xie, Haibo Zhang, (unknown), Peng Zheng, (unknown), Chi Ma, Likun Chen	30
7	Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients 2021 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Wenfeng Fang, Jianwen Li, Delan Li, Changzheng Wang, Quanfei Huang, Min Huang, Wei Zhuang, Xueding Wang, Likun Chen	12
8	Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience 2021 ·Translational Lung Cancer Research ·Xinqing Lin, Haiyi Deng, Likun Chen, Di Wu, Xiaobo Chen, (unknown), Tao Chen, Xiaohong Xie, Zhanhong Xie, Ming Liu, Ming Ouyang, Yinyin Qin, Shiyue Li, Nanshan Zhong, Jeffrey P. Gregg, Nobuyuki Horita, Yong Song, Chengzhi Zhou	12
9	MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study 2020 ·Translational Oncology ·Xuewen Liu, (unknown), Yuming Rong, Ning Lyu, C. Xu, Fang Wang, Wenyong Sun, (unknown), Jingping Yuan, Huijuan Wang, Wenxian Wang, Wenbin Huang, Jianping Xu, (unknown), Likun Chen	16
10	Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma 2020 ·Oncogene ·Xuewen Liu, Fang Wang, C. Xu, Xinru Chen, Xue Hou, (unknown), Pansong Li, Zhi Xie, Yongdong Liu, Lianpeng Chang, Yanfang Guan, Xu‐Chao Zhang, Ling Yang, Hui Wang, Xin Yi, Jianjun Zhang, Xuefeng Xia, César A. Moran, Likun Chen	18
11	Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib 2019 ·Lung Cancer ·Jun Zhao, Gen Lin, Minglei Zhuo, (unknown), Liyun Miao, Likun Chen, Aiping Zeng, Rong Yin, Yangming Ou, Zhihui Shi, Jie Yin, Wen Gao, Jianhua Chen, Xiangdong Zhou, Yong Zeng, Xiang Liu, (unknown), Rongrong Chen, Xuefeng Xia, David P. Carbone	30
12	Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials breakdown → 2018 ·The Lancet Oncology ·Wenfeng Fang, Yunpeng Yang, Yuxiang Ma, Shaodong Hong, Lizhu Lin, Xiaohui He, Jianping Xiong, Ping Li, Hongyun Zhao, Yan Huang, Yang Zhang, Likun Chen, Ningning Zhou, Yuanyuan Zhao, Xue Hou, Qing Yang, Li Zhang	326
13	Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor 2017 ·Translational Oncology ·Xinru Chen, Yu Zhang, Jiabin Lu, C. Xu, (unknown), Fang Wang, Wenyong Sun, (unknown), Jingping Yuan, Huijuan Wang, Hui Wang, Xuewen Liu, Likun Chen	22
14	Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo , and Ex Vivo 2016 ·Molecular Cancer Therapeutics ·Zhen Chen, Yifan Chen, Meng Xu, Likun Chen, Xu Zhang, Kenneth K.W. To, Hongyun Zhao, Fang Wang, Zhongjun Xia, Xiaoqin Chen, Liwu Fu	45
15	Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting 2016 ·Medicine ·Zhihuang Hu, Wenhua Liang, Yunpeng Yang, Dorothy Keefe, Yuxiang Ma, Yuanyuan Zhao, Cong Xue, Yan Huang, Hongyun Zhao, Likun Chen, Alexandre Chan, Li Zhang	18
16	Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenase 2016 ·OncoTargets and Therapy ·Tao Qin, Ningning Zhou, Xiao-Xiao Dinglin, Yuanyuan Zhao, Likun Chen, (unknown), Huai Liu	6
17	Applying "paradigm contending" to tourism research: taking "authenticity" tourism research as an example. 2013 ·Luyou xuekan ·Likun Chen	0
18	A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours 2011 ·British Journal of Clinical Pharmacology ·Xuexin He, (unknown), He Huang, (unknown), Likun Chen, (unknown), Jiajia Huang, Jing Zhan, Tong-Yu Lin	29
19	Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib 2010 ·Medical Oncology ·Feng‐Hua Wang, Yang Zhang, Hongyun Zhao, Likun Chen, Yan-Xia Shi, Li Zhang	4
20	Brain Radiotherapy Combined with Sequential Chemotherapy in Non-Small-Cell Lung Cancer Patients with Brain Metastases 2009 ·SHILAP Revista de lepidopterología ·Likun Chen, Qunying Yang, Ying Liang, Guozhen Liu, Hai Liao, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact